The burgeoning UK landscape surrounding entheogens is increasingly intricate, demanding careful exploration. While scientific inquiry into compounds like psilocybin and copyright continues to progress, and patient opportunity via private clinics is growing, the policy framework remains uncertain. This presents a challenging situation for both seeke